{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:29:20Z","timestamp":1780536560361,"version":"3.54.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Erectile dysfunction (ED) is a known precursor and sequela of cardiovascular disease (CVD), with ED severity predicting CVD severity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>This study aimed to evaluate the utility of ceramide levels in patients with ED.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We initiated ceramide testing in all patients with ED. We retrospectively analyzed ceramide levels from electronic records and stratified by severity of symptoms using the erectile function domain of the International Index of Erectile Function (IIEF).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>The study aimed to determine whether abnormal ceramide levels were associated with ED severity and increased cardiovascular risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Three hundred and fifty-four patients were reviewed, of whom 253 (71.5%) had moderate or higher ED. A statistically significant difference in abnormal ceramide values was found in patients with moderate to severe symptoms, and the odds of getting an abnormal ceramide test were increased based on the IIEF scoring alone (odds ratio [OR] 2.3 [1.04-5.12]; P-value\u2009=\u2009.034).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>Serum ceramide testing could be beneficial in identifying cardiovascular risk in men with ED, potentially prompting cardiac referrals and lifestyle modifications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths and Limitations<\/jats:title>\n                  <jats:p>The strengths of this study include a large sample size and the use of a well-established scale, while the limitations include the retrospective nature of the study and the need for further research to validate the findings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patients undergoing management for ED may benefit from serum ceramide testing and subsequent cardiac referral.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdaf182","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T08:57:31Z","timestamp":1759654651000},"page":"1750-1756","source":"Crossref","is-referenced-by-count":1,"title":["Ceramide test in patients with erectile dysfunction to assess cardiovascular risk"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7186-164X","authenticated-orcid":false,"given":"Andres","family":"Guillen Lozoya","sequence":"first","affiliation":[{"name":"Department of Urology, Mayo Clinic Rochester , Rochester, Minnesota , 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai","family":"Dumbrava","sequence":"additional","affiliation":[{"name":"Mayo Clinic Alix School of Medicine , Rochester, Minnesota , 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Bonakdarhashemi","sequence":"additional","affiliation":[{"name":"Department of Urology, Mayo Clinic Rochester , Rochester, Minnesota , 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayson","family":"Kemble","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Nebraska Medical Center , Omaha, Nebraska , 68198,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevann","family":"Helo","sequence":"additional","affiliation":[{"name":"Department of Urology, Mayo Clinic Rochester , Rochester, Minnesota , 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ziegelmann","sequence":"additional","affiliation":[{"name":"Department of Urology, Mayo Clinic Rochester , Rochester, Minnesota , 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Urology, Mayo Clinic Rochester , Rochester, Minnesota , 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Vasile","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Mayo Clinic Rochester , Rochester, Minnesota , 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Kopecky","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Mayo Clinic Rochester , Rochester, Minnesota , 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"K\u00f6hler","sequence":"additional","affiliation":[{"name":"Department of Urology, Mayo Clinic Rochester , Rochester, Minnesota , 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"issue":"1","key":"2025100504572562600_ref1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1001\/jama.1993.03510010089036","article-title":"Impotence. NIH consensus development panel on impotence","volume":"270","author":"NIH Consensus Conference","year":"1993","journal-title":"JAMA."},{"issue":"2","key":"2025100504572562600_ref2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jsxm.2015.12.019","article-title":"Definitions of sexual dysfunctions in women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015","volume":"13","author":"McCabe","year":"2016","journal-title":"J Sex Med"},{"issue":"1","key":"2025100504572562600_ref3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S0022-5347(17)34871-1","article-title":"Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study","volume":"151","author":"Feldman","year":"1994","journal-title":"J Urol"},{"issue":"5","key":"2025100504572562600_ref4","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1111\/j.1743-6109.2010.01744.x","article-title":"Male sexuality and cardiovascular risk. A cohort study in patients with erectile dysfunction","volume":"7","author":"Corona","year":"2010","journal-title":"J Sex Med"},{"issue":"2","key":"2025100504572562600_ref5","doi-asserted-by":"crossref","first-page":"qfad010","DOI":"10.1093\/sexmed\/qfad010","article-title":"Quantifying the number of US men with erectile dysfunction who are potential candidates for penile prosthesis implantation","volume":"11","author":"Rojanasarot","year":"2023","journal-title":"Sex Med"},{"issue":"3","key":"2025100504572562600_ref6","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.juro.2018.05.004","article-title":"Erectile dysfunction: AUA guideline","volume":"200","author":"Burnett","year":"2018","journal-title":"J Urol"},{"issue":"4","key":"2025100504572562600_ref7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jsxmed\/qdae008","article-title":"Erectile dysfunction prevalence in the United States: report from the 2021 National Survey of Sexual Wellbeing","volume":"21","author":"Mark","year":"2024","journal-title":"J Sex Med"},{"issue":"23","key":"2025100504572562600_ref8","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1001\/jama.294.23.2996","article-title":"Erectile dysfunction and subsequent cardiovascular disease","volume":"294","author":"Thompson","year":"2005","journal-title":"JAMA."},{"issue":"3","key":"2025100504572562600_ref9","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S0302-2838(03)00305-1","article-title":"Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease","volume":"44","author":"Montorsi","year":"2003","journal-title":"Eur Urol"},{"issue":"12B","key":"2025100504572562600_ref10","doi-asserted-by":"publisher","first-page":"19m","DOI":"10.1016\/j.amjcard.2005.07.006","article-title":"The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease","volume":"96","author":"Montorsi","year":"2005","journal-title":"Am J Cardiol"},{"issue":"22","key":"2025100504572562600_ref11","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1093\/eurheartj\/ehl142","article-title":"Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial","volume":"27","author":"Montorsi","year":"2006","journal-title":"Eur Heart J"},{"issue":"2","key":"2025100504572562600_ref12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4065\/84.2.108","article-title":"A population-based, longitudinal study of erectile dysfunction and future coronary artery disease","volume":"84","author":"Inman","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2025100504572562600_ref13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1743-6109.2009.01576.x","article-title":"Erectile dysfunction as a predictor for subsequent atherosclerotic cardiovascular events: findings from a linked-data study","volume":"7","author":"Chew","year":"2010","journal-title":"J Sex Med"},{"issue":"10","key":"2025100504572562600_ref14","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1111\/j.1743-6109.2012.02869.x","article-title":"Is erectile dysfunction a reliable proxy of general male health status? The case for the International Index of Erectile Function-Erectile Function domain","volume":"9","author":"Salonia","year":"2012","journal-title":"J Sex Med"},{"issue":"4","key":"2025100504572562600_ref15","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1161\/ATVBAHA.120.315530","article-title":"Ceramide scores predict cardiovascular risk in the community","volume":"41","author":"Vasile","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"2025100504572562600_ref16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12944-015-0053-y","article-title":"Sphingolipids in cardiovascular diseases and metabolic disorders","volume":"14","author":"Borodzicz","year":"2015","journal-title":"Lipids Health Dis"},{"issue":"11","key":"2025100504572562600_ref17","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1161\/ATVBAHA.119.313099","article-title":"Elevated plasma ceramides are associated with higher white matter hyperintensity volume\u2014brief report","volume":"39","author":"Mielke","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2025100504572562600_ref18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/MCA.0000000000000079","article-title":"Elevation of ceramide and activation of secretory acid sphingomyelinase in patients with acute coronary syndromes","volume":"25","author":"Pan","year":"2014","journal-title":"Coron Artery Dis"},{"issue":"25","key":"2025100504572562600_ref19","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1093\/eurheartj\/ehw148","article-title":"Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol","volume":"37","author":"Laaksonen","year":"2016","journal-title":"Eur Heart J"},{"issue":"3","key":"2025100504572562600_ref20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/eurheartj\/ehz387","article-title":"Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients","volume":"41","author":"Hilvo","year":"2020","journal-title":"Eur Heart J"},{"key":"2025100504572562600_ref21","doi-asserted-by":"publisher","first-page":"570628","DOI":"10.3389\/fendo.2020.570628","article-title":"Ceramides and ceramide scores: clinical applications for cardiometabolic risk stratification","volume":"11","author":"Hilvo","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"2025100504572562600_ref22","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.mayocp.2024.06.002","article-title":"The Princeton IV Consensus recommendations for the management of erectile dysfunction and cardiovascular disease","volume":"99","author":"K\u00f6hler","year":"2024","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"2025100504572562600_ref23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1161\/JAHA.117.007931","article-title":"Ceramide remodeling and risk of cardiovascular events and mortality","volume":"7","author":"Peterson","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"2025100504572562600_ref24","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1161\/ATVBAHA.116.307497","article-title":"Circulating ceramides predict cardiovascular outcomes in the population-based FINRISK 2002 cohort","volume":"36","author":"Havulinna","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"2025100504572562600_ref25","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.2337\/db23-0052","article-title":"Ceramides as risk markers for future cardiovascular events and all-cause mortality in long-standing type 1 diabetes","volume":"72","author":"Wretlind","year":"2023","journal-title":"Diabetes."},{"issue":"6","key":"2025100504572562600_ref26","doi-asserted-by":"publisher","first-page":"768","DOI":"10.7326\/M23-2781","article-title":"Associations of testosterone and related hormones with all-cause and cardiovascular mortality and incident cardiovascular disease in men: individual participant data meta-analyses","volume":"177","author":"Yeap","year":"2024","journal-title":"Ann Intern Med"},{"issue":"11","key":"2025100504572562600_ref27","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1161\/ATVBAHA.120.314796","article-title":"Associations between plasma ceramides and cerebral microbleeds or lacunes","volume":"40","author":"Ighodaro","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025100504572562600_ref28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.brainresbull.2020.03.009","article-title":"Plasma levels of ceramides relate to ischemic stroke risk and clinical severity","volume":"158 (5)","author":"Gui","year":"2020","journal-title":"Brain Res Bull"},{"issue":"11","key":"2025100504572562600_ref29","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1161\/CIRCULATIONAHA.108.843979","article-title":"Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia\/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide","volume":"120","author":"Salloum","year":"2009","journal-title":"Circulation."},{"key":"2025100504572562600_ref30","author":"Mayo Clinic Laboratories. MI-Heart Ceramides, Plasma \u2013 Test ID: CERAM"},{"key":"2025100504572562600_ref31","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaf093","article-title":"Ceramides in cardiovascular disease\u2014emerging role as independent risk predictors and novel therapeutic targets","author":"Klingenberg","year":"2025","journal-title":"Cardiovasc Res"},{"issue":"6","key":"2025100504572562600_ref32","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/joim.20090","article-title":"Metabolomics in cardiometabolic diseases: key biomarkers and therapeutic implications for insulin resistance and diabetes","volume":"297","author":"Rizo-Roca","year":"2025","journal-title":"J Intern Med"},{"issue":"1","key":"2025100504572562600_ref33","doi-asserted-by":"publisher","first-page":"2496795","DOI":"10.1080\/07853890.2025.2496795","article-title":"Impact of sodium-glucose cotransporter-2 inhibitors on aging biomarkers and plasma ceramide levels in type 2 diabetes: beyond glycemic control","volume":"57","author":"Shalaby","year":"2025","journal-title":"Ann Med"},{"issue":"7","key":"2025100504572562600_ref34","doi-asserted-by":"publisher","first-page":"e022852","DOI":"10.1161\/JAHA.121.022852","article-title":"Plasma ceramide levels are elevated in patients with early coronary atherosclerosis and endothelial dysfunction","volume":"11","author":"Akhiyat","year":"2022","journal-title":"J Am Heart Assoc"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/22\/10\/1750\/63956844\/qdaf182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/22\/10\/1750\/63956844\/qdaf182.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T08:57:32Z","timestamp":1759654652000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/22\/10\/1750\/8222478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,8,5]]},"published-print":{"date-parts":[[2025,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdaf182","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,8,5]]}}}